c-Met/HGFR

c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. c-Met is a membrane receptor that is essential for embryonic development and wound healing. Hepatocyte growth factor (HGF) is the only known ligand of the c-Met receptor. c-Met is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymal origin. Upon HGF stimulation, c-Met induces several biological responses that collectively give rise to a program known as invasive growth.
### c-Met/HGFR Inhibitors & Activators

<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Size</th>
<th>Clinical Data</th>
<th>Purity</th>
<th><strong>Clinical Data</strong></th>
<th>Purity</th>
<th><strong>Clinical Data</strong></th>
<th>Purity</th>
<th><strong>Clinical Data</strong></th>
<th>Purity</th>
<th><strong>Clinical Data</strong></th>
<th>Purity</th>
<th><strong>Clinical Data</strong></th>
<th>Purity</th>
<th><strong>Clinical Data</strong></th>
<th>Purity</th>
<th><strong>Clinical Data</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>2-Phospho-L-ascorbic acid trisodium (L-Ascorbic acid 2-phosphate trisodium)</td>
<td>HY-107837</td>
<td>10 mM × 1 mL, 500 mg, 1 g</td>
<td>No Development Reported</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.66%</td>
<td>99.36%</td>
<td>99.66%</td>
<td>99.36%</td>
<td>99.66%</td>
<td>99.36%</td>
<td>99.66%</td>
<td>99.36%</td>
<td>99.66%</td>
<td>99.36%</td>
<td>99.66%</td>
<td>99.36%</td>
</tr>
<tr>
<td>AMG-208</td>
<td>HY-12035</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td>Phase 2</td>
<td>99.34%</td>
<td>99.34%</td>
<td>99.34%</td>
<td>99.34%</td>
<td>99.34%</td>
<td>99.34%</td>
<td>99.34%</td>
<td>99.34%</td>
<td>99.34%</td>
<td>99.34%</td>
<td>99.34%</td>
<td>99.34%</td>
<td>99.34%</td>
<td>99.34%</td>
</tr>
<tr>
<td>AMG-337</td>
<td>HY-18696</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
<td>Phase 2</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
</tr>
<tr>
<td>Amuvatinib (MP470; HPK 56)</td>
<td>HY-10206</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td>Phase 2</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
<td>99.36%</td>
</tr>
<tr>
<td>BAY-474</td>
<td>HY-133083</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td>No Development Reported</td>
<td>&gt;98%</td>
<td>&gt;98%</td>
<td>&gt;98%</td>
<td>&gt;98%</td>
<td>&gt;98%</td>
<td>&gt;98%</td>
<td>&gt;98%</td>
<td>&gt;98%</td>
<td>&gt;98%</td>
<td>&gt;98%</td>
<td>&gt;98%</td>
<td>&gt;98%</td>
<td>&gt;98%</td>
<td>&gt;98%</td>
</tr>
<tr>
<td>BMS 777607 (BMS 817378)</td>
<td>HY-12076</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td>Phase 2</td>
<td>99.48%</td>
<td>99.48%</td>
<td>99.48%</td>
<td>99.48%</td>
<td>99.48%</td>
<td>99.48%</td>
<td>99.48%</td>
<td>99.48%</td>
<td>99.48%</td>
<td>99.48%</td>
<td>99.48%</td>
<td>99.48%</td>
<td>99.48%</td>
<td>99.48%</td>
</tr>
<tr>
<td>BMS-794833</td>
<td>HY-10497</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td>No Development Reported</td>
<td>99.82%</td>
<td>99.82%</td>
<td>99.82%</td>
<td>99.82%</td>
<td>99.82%</td>
<td>99.82%</td>
<td>99.82%</td>
<td>99.82%</td>
<td>99.82%</td>
<td>99.82%</td>
<td>99.82%</td>
<td>99.82%</td>
<td>99.82%</td>
<td>99.82%</td>
</tr>
<tr>
<td>Bozitinib (PLB-1001; CBT-101)</td>
<td>HY-125017</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
<td>Phase 2</td>
<td>99.66%</td>
<td>99.66%</td>
<td>99.66%</td>
<td>99.66%</td>
<td>99.66%</td>
<td>99.66%</td>
<td>99.66%</td>
<td>99.66%</td>
<td>99.66%</td>
<td>99.66%</td>
<td>99.66%</td>
<td>99.66%</td>
<td>99.66%</td>
<td>99.66%</td>
</tr>
</tbody>
</table>

**Notes:**
- **Cat. No.** represents the catalog number for the chemical compound.
- **Clinical Data:** indicates whether the development status is reported or not.
- **Purity:** specifies the purity of the compound.
- **Size:** provides the available sizes for the compound.
**BPI-9016M**

BPI-9016M is a potent, orally active, and selective dual c-Met and AXL tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma.

- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg

**c-Met inhibitor 1**

c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.

- **Purity:** 98.01%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

**c-Met-IN-2**

c-Met-IN-2 is a potent, selective and orally available c-Met inhibitor, with an IC_{50} of 0.6 nM, with antitumor activity.

- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg

**Capmatinib**

Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC_{50}=0.13 nM).

- **Purity:** 99.84%
- **Clinical Data:** Phase 3
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

**Crizotinib**

Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC_{50}s of 20 and 8 nM, respectively.

- **Purity:** 99.97%
- **Clinical Data:** Launched
- **Size:** 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

**CABOZANTINIB (XL184; BMS-907351)**

Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flk1 with IC_{50}s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

- **Purity:** 99.85%
- **Clinical Data:** Launched
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

**CEP-40783**

CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with IC_{50} values of 7 nM and 12 nM, respectively.

- **Purity:** 99.22%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

www.MedChemExpress.com
<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSF1R-IN-2</td>
<td>HY-111787</td>
<td>CSF1R-IN-2 (compound 5) is an oral-active inhibitor of SRC, MET and c-FMS, with IC₅₀ values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively.</td>
</tr>
<tr>
<td>Purity:</td>
<td>99.97%</td>
<td>Clinical Data: No Development Reported</td>
</tr>
<tr>
<td>Size:</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td></td>
</tr>
<tr>
<td>Dihexa</td>
<td>HY-16969</td>
<td>Dihexa, an oligopeptide drug, is an orally active and blood-brain barrier-permeable angiotensin IV analog. Dihexa binds to hepatocyte growth factor (HGF) with high affinity (Kᵢ₅₀ = 65 pM) and potentiates its activity at its receptor, c-Met.</td>
</tr>
<tr>
<td>Purity:</td>
<td>98.74%</td>
<td>Clinical Data: No Development Reported</td>
</tr>
<tr>
<td>Size:</td>
<td>10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td></td>
</tr>
<tr>
<td>EGFR-IN-8</td>
<td>HY-126320</td>
<td>EGFR-IN-8 is a dual EGFR and c-Met inhibitor, compound 48. EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC.</td>
</tr>
<tr>
<td>Purity:</td>
<td>98.31%</td>
<td>Clinical Data: No Development Reported</td>
</tr>
<tr>
<td>Size:</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td></td>
</tr>
<tr>
<td>Ensartinib</td>
<td>HY-103714A</td>
<td>Ensartinib (X-396) is a potent and dual ALK/MET inhibitor with IC₅₀ values of 0.4 nM and 0.74 nM, respectively.</td>
</tr>
<tr>
<td>Purity:</td>
<td>&gt;98%</td>
<td>Clinical Data: No Development Reported</td>
</tr>
<tr>
<td>Size:</td>
<td>1 mg, 5 mg</td>
<td></td>
</tr>
<tr>
<td>Ensartinib hydrochloride (X-396 hydrochloride)</td>
<td>HY-103714A</td>
<td>Ensartinib hydrochloride (X-396 hydrochloride) is a potent and dual ALK/MET inhibitor with IC₅₀ values of 0.4 nM and 0.74 nM, respectively.</td>
</tr>
<tr>
<td>Purity:</td>
<td>98.51%</td>
<td>Clinical Data: No Development Reported</td>
</tr>
<tr>
<td>Size:</td>
<td>10 mM × 1 mL, 2 mg, 5 mg, 10 mg</td>
<td></td>
</tr>
<tr>
<td>Glesatinib</td>
<td>HY-19642</td>
<td>Glesatinib (MGCD265) is an orally active, potent MET/SMO dual inhibitor. Glesatinib, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).</td>
</tr>
<tr>
<td>Purity:</td>
<td>&gt;98%</td>
<td>Clinical Data: No Development Reported</td>
</tr>
<tr>
<td>Size:</td>
<td>1 mg, 5 mg</td>
<td></td>
</tr>
<tr>
<td>Glesatinib hydrochloride (MGCD265 hydrochloride)</td>
<td>HY-19642A</td>
<td>Glesatinib hydrochloride (MGCD265 hydrochloride) is an orally active, potent MET/SMO dual inhibitor. Glesatinib hydrochloride, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).</td>
</tr>
<tr>
<td>Purity:</td>
<td>98.25%</td>
<td>Clinical Data: Phase 2</td>
</tr>
<tr>
<td>Size:</td>
<td>10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
<td></td>
</tr>
<tr>
<td>Glumetinib</td>
<td>HY-116000</td>
<td>Glumetinib (SCC244) is a potent and highly selective c-Met kinase inhibitor with an IC₅₀ of 0.42 nM. Glumetinib shows antitumor activity and a superior safety margin.</td>
</tr>
<tr>
<td>Purity:</td>
<td>98.15%</td>
<td>Clinical Data: No Development Reported</td>
</tr>
<tr>
<td>Size:</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td></td>
</tr>
<tr>
<td>Golvatinib</td>
<td>HY-13068</td>
<td>Golvatinib (E-7050) is a potent dual inhibitor of both c-Met and VEGFR2 kinases with IC₅₀ values of 14 and 16 nM, respectively.</td>
</tr>
<tr>
<td>Purity:</td>
<td>99.29%</td>
<td>Clinical Data: Phase 2</td>
</tr>
<tr>
<td>Size:</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td></td>
</tr>
</tbody>
</table>
JNJ-38877605
Cat. No.: HY-50683
JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.
Purity: 99.95%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Meleagrin
Cat. No.: HY-N6797
Meleagrin is a roquefortine C-derived alkaloid produced by fungi of the genus Penicillium and has antimicrobial and anti-proliferative activities. Meleagrin is a class of FabI inhibitor.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Merestinib
Cat. No.: HY-15514
Merestinib (LY2801653) is a potent, orally bioavailable inhibitor (IC50 = 2 nM) with anti-tumor activities.
Purity: 99.99%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Merestinib dihydrochloride
(LY2801653 dihydrochloride)
Cat. No.: HY-15514A
Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable c-Met inhibitor (Kd = 2 nM) with anti-tumor activities.
Purity: 99.02%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MK-2461
Cat. No.: HY-50703
MK-2461 is a novel ATP-competitive multitargeted inhibitor of activated c-Met with a mean IC50 of 2.5 nM.
Purity: 99.92%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MK-8033
Cat. No.: HY-13299
MK-8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.
Purity: >98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MK-8033 hydrochloride
Cat. No.: HY-13299A
MK8033 Hcl is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.
Purity: 99.70%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg
Ningetinib

Cat. No.: HY-107145A

Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC₅₀ of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.

Purity: 98.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ningetinib Tosylate

Cat. No.: HY-107145

Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC₅₀ of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.

Purity: 99.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Norleual

Cat. No.: HY-P1415

Norleual is an angiotensin IV analog. Norleual is a highly potent HGF/c-MET inhibitor (IC₅₀=3 pmM). Norleual inhibits HGF-induced MDCK cell proliferation and invasion in vitro. Norleual also is an AT4 receptor antagonist; disrupts LTP stabilization. Antiangiogenic.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NPS-1034

Cat. No.: HY-100509

NPS-1034 is a dual inhibitor of AXL and MET with IC₅₀ of 10.3 and 48 nM, respectively.

Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NVP-BVU972

Cat. No.: HY-15456

NVP-BVU972 is a selective and potent Met inhibitor (IC₅₀ = 14 nM). Antitumor agents.

Purity: 98.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PF-04217903 methanesulfonate

Cat. No.: HY-12017A

PF-04217903 methanesulfonate is a potent ATP-competitive c-Met kinase inhibitor with Kᵢ of 4.8 nM for human c-Met. PF-04217903 shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties.

Purity: 99.87%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-04217903 phenolsulfonate

Cat. No.: HY-12017B

PF-04217903 phenolsulfonate is a potent ATP-competitive c-Met kinase inhibitor with Kᵢ of 4.8 nM for human c-Met. PF-04217903 phenolsulfonate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties.

Purity: 98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PHA-665752

Cat. No.: HY-11107

PHA-665752 is a selective, ATP-competitive, and active-site inhibitor of the catalytic activity of c-Met kinase (Kᵢ=4 nM; IC₅₀=9 nM). PHA-665752 exhibits >50-fold selectivity for c-Met compared with a panel of diverse tyrosine and serine-threonine kinases.

Purity: 99.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

S49076

Cat. No.: HY-12965

S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC₅₀ values below 20 nM.

Purity: 98.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg
SAR125844

Cat. No.: HY-16446

SAR125844 is a potent, highly selective, reversible and ATP-competitive MET receptor tyrosine kinase (RTK) inhibitor, with an IC50 of 4.2 nM. Shows inhibition of MET autophosphorylation in cell-based assays.

Purity: 99.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Savolitinib

(Volitinib; HMPL-504; AZD-6094)

Cat. No.: HY-15959

Savolitinib (AZD-6094) is a potent, highly selective, and orally bioavailable c-Met inhibitor with IC50 of 5 nM and 3 nM for c-Met and p-Met, respectively.

Purity: 99.29%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SCR-1481B1

(c-Met inhibitor 2)

Cat. No.: HY-18711A

SCR-1481B1 (c-Met inhibitor 2) is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor.

Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SGX-523

Cat. No.: HY-12019

SGX-523 is a selective Met inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α. IC50 value: 4 nM Target: Met in vitro: SGX-523 belongs to the class of c-Met/hepatocyte growth factor receptor (HGFR) tyrosine kinase inhibitors.

Purity: >99.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

SRI 31215 TFA

Cat. No.: HY-114363A

SRI 31215 (TFA), a triplex inhibitor of matriptase, hepsin and hepatocyte growth factor activator (HGFA) with IC50s of 0.69 μM, 0.65 μM, 0.3 μM, blocks pro-HGF activation and thus mimics the activity of HAI-1/2.

Purity: 99.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SU11274

(PKI-SU11274)

Cat. No.: HY-12014

SU11274 is a selective Met inhibitor with IC50 of 10 nM, but has no effects on PDGFRβ, EGFR or Tie2.

Purity: 98.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

TAS-115

Cat. No.: HY-12423

TAS-115 is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TAS-115 mesylate

(TAS-115 methanesulfonate)

Cat. No.: HY-12423A

TAS-115 mesylate is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.

Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tepotinib

(EMD-1214063)

Cat. No.: HY-14721

Tepotinib (EMD-1214063) is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.

Purity: 99.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tivantinib

(Arzon; EMD-1214063)

Cat. No.: HY-50686

Tivantinib is a highly selective c-Met tyrosine kinase inhibitor with a Ki of 355 nM.

Purity: 99.67%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

www.MedChemExpress.com
<table>
<thead>
<tr>
<th>Tyrosine kinase inhibitor</th>
<th>X-376</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cat. No.</strong></td>
<td>HY-10421</td>
</tr>
<tr>
<td><strong>A Tyrosine kinase inhibitor.</strong></td>
<td>X-376 is a potent and highly specific ALK tyrosine kinase inhibitor (TKI) ( \text{IC}<em>{50}=0.61 \text{ nM} ). X-376 is a less potent inhibitor of MET ( \text{IC}</em>{50}=0.69 \text{ nM} ). X-376 displays potent anti-tumor activity.</td>
</tr>
<tr>
<td><strong>Purity:</strong></td>
<td>99.36%</td>
</tr>
<tr>
<td><strong>Clinical Data:</strong></td>
<td>No Development Reported</td>
</tr>
<tr>
<td><strong>Size:</strong></td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 25 mg</td>
</tr>
</tbody>
</table>